Yousif Capital Management’s TG Therapeutics TGTX Stock Holding History

Yousif Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2M	Sell	36,480 -717	-2%	-$29.3K	0.02%	689
2026 Q1	$1.24M	Sell	37,197 -774	-2%	-$23.1K	0.01%	928
2025 Q4	$1.17M	Sell	37,971 -5,383	-12%	-$176K	0.01%	997
2025 Q3	$1.57M	Sell	43,354 -8,523	-16%	-$281K	0.02%	851
2025 Q2	$1.87M	Buy	51,877 +1,345	+3%	+$50.1K	0.02%	776
2025 Q1	$1.99M	Sell	50,532 -1,051	-2%	-$35.4K	0.02%	721
2024 Q4	$1.55M	Sell	51,583 -977	-2%	-$28K	0.02%	895
2024 Q3	$1.23M	Buy	+52,560	New	+$1.15M	0.01%	1058

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Yousif Capital Management's TGTX Position: Q2 2026 in Review

Yousif Capital Management reduced its TG Therapeutics (TGTX) stake by 1.9% in Q2 2026, selling an estimated $29.3K and leaving 36,480 shares worth $2M. The position accounts for 0.02% of the portfolio, ranked #689.

Yousif Capital Management first reported a position in TGTX in Q3 2024 and has held it in 8 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Yousif Capital Management held 36,480 shares of TG Therapeutics worth $2M as of Q2 2026.
Yousif Capital Management sold 717 TG Therapeutics shares in Q2 2026, an estimated $29.3K.
TG Therapeutics made up 0.02% of Yousif Capital Management's portfolio in Q2 2026, its #689 holding.
Yousif Capital Management first reported a position in TG Therapeutics in Q3 2024 and has held it in 8 quarters since.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Yousif Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.